Investigational drug · Phase 3
NTI164
Also called: FEN164
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Rett Syndrome, Autism, Autism Spectrum Disorder.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
2 still active
All registered trials
6
Any phase or sponsor naming "NTI164"
First trial start
2023
Jun 2, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NTI164", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rett Syndrome
- Autism
- Autism Spectrum Disorder
- Autism Disorder
- RETT Syndrome With Proven MECP2 Mutation
- PANS Pediatric Acute-Onset Neuropsychiatric Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "NTI164" as an intervention, largest first.
- NTI164 in Autism Spectrum DisorderPivotal-lookingNot yet recruiting
Fenix Innovation GroupIndustry
NCT07257939 · 200 participants (planned) · Start Sep 30, 2026 · Primary completion Jul 1, 2029
Drug: NTI164; Placebo · For: Autism; Autism Spectrum Disorder; Autism Disorder
Sites: Brisbane, Australia; Sunshine Coast, Australia; Clayton, Australia
- Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum DisorderPivotal-lookingCompleted
Fenix Innovation GroupIndustry
NCT05626959 · 54 participants · Start Nov 30, 2022 · Primary completion Mar 1, 2024
Drug: NTI164 · For: Autism Spectrum Disorder
Sites: Clayton, Australia
- Efficacy and Safety of NTI164 in Children and Young Adults With Rett SyndromePivotal-lookingNot yet recruiting
Fenix Innovation GroupIndustry
NCT07257978 · 40 participants (planned) · Start Jul 1, 2027 · Primary completion Oct 1, 2028
Drug: NTI164; Placebo · For: RETT Syndrome With Proven MECP2 Mutation; Rett Syndrome
Sites: Clayton, Australia
Fenix Innovation GroupIndustry
NCT06621888 · 18 participants · Start Jun 2, 2023 · Primary completion Dec 1, 2025
Drug: NTI164 · For: PANS Pediatric Acute-Onset Neuropsychiatric Syndrome
Sites: Sydney, Australia; Melbourne, Australia
Fenix Innovation GroupIndustry
NCT06621043 · 14 participants · Start Sep 20, 2023 · Primary completion Dec 1, 2025
Drug: NTI164 · For: Rett Syndrome
Sites: Sydney, Australia
- NTI164 Human PK StudyCompleted
Fenix Innovation GroupIndustry
NCT06713447 · 12 participants · Start Feb 1, 2024 · Primary completion Jun 1, 2025
Drug: NTI164 · For: Healthy; Healthy Volunteer
Sites: Adelaide, Australia
Newest research
PubMed records naming it or its code names, newest first.
- NTI164, a novel medicinal cannabis extract, improves core symptoms of autism spectrum disorder: Results from a double-blind, randomised, controlled trial (The Harmony study).
Keating BA, Ogru Y, Isikgel E, et al. · Neurotherapeutics 2026
- Towards treatments targeting the gut to improve behavioural outcomes in autism spectrum disorder.
Munira MS, Stevens JE, Shahin W, et al. · J Neural Transm (Vienna) 2026
- Medicinal cannabis plant extract (NTI164) modifies epigenetic, ribosomal, and immune pathways in paediatric acute-onset neuropsychiatric syndrome.
Keating BA, Han VX, Nishida H, et al. · Neurotherapeutics 2026
- Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) Improves Symptoms of Rett Syndrome: An Open-Label Study.
Keating BA, Ogru Y, Duthy TG, et al. · J Paediatr Child Health 2025
- Evaluation of the Efficacy of a Full-Spectrum Low-THC Cannabis Plant Extract Using In Vitro Models of Inflammation and Excitotoxicity.
Ross-Munro E, Isikgel E, Fleiss B · Biomolecules 2024
Also in development for Rett Syndrome
- BionetideNA-921Phase 32 trials
Biomed Industries, Inc. · Rett Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.